| Date | Title | Description |
| 10.09.2024 | MRM Health appoints Grégoire Franoux as Chief Business Officer and adds Ron Robison to its Board of Directors | GHENT, Belgium, September 10, 2024 – MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to ... |
| 25.07.2024 | Oxurion Share Consolidation | Oxurion Share Consolidation
Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET Oxurion NV (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, authorized by the Gener... |
| 24.07.2024 | Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 | Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024
Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraor... |
| 19.07.2024 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of... |
| 19.07.2024 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of... |
| 14.05.2024 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of... |
| 15.04.2024 | Publication Annual Report – Annual Shareholders' Meeting | Publication Annual Report – Annual Shareholders' Meeting
Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for th... |
| 10.04.2024 | Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up | - |
| 25.03.2024 | OXURION announces its presence at the Paris SmallCap event on March 28, 2024. | OXURION announces its presence at the Paris SmallCap
event on March 28, 2024.
Leuven, BELGIUM - March 25, 2024 - 7:00 p.m, Oxurion NV (Euronext Brussels : OXUR), a Leuven-based biopharmaceutical company, is pleased to announce its participa... |
| 21.03.2024 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas | Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part o... |
| 13.03.2024 | Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC | - |
| 07.03.2024 | Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC | - |
| 05.03.2024 | Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up | - |
| 04.03.2024 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas | Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part o... |
| 19.01.2024 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas | Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commit... |
| 25.10.2023 | Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial | - |
| 25.10.2023 | Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial | Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retin... |
| 07.08.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitm... |
| 04.08.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commit... |
| 25.07.2023 | Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB | - |
| 06.07.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million C... |
| 22.06.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million C... |
| 15.06.2023 | Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC | /EIN News/ -- Leuven, BELGIUM, Boston, MA, US – June 15, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vasc... |
| 15.06.2023 | Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC | - |
| 15.06.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million C... |
| 31.05.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 22 convertible bonds in Oxurion resulting in a EUR 550,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million ... |
| 22.05.2023 | Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC | - |
| 12.05.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million ... |
| 05.05.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS | /EIN News/ -- Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 14 convertible bonds in Oxurion resulting in a EUR 350,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million ... |
| 27.04.2023 | Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC | /EIN News/ -- Leuven, BELGIUM, Boston, MA, US – April 27, 2023 – 7:00 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in ... |
| 27.04.2023 | Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC | - |
| 07.04.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS | Regulated Information - Denominator
Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commit... |
| 20.03.2023 | Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL | /EIN News/ -- Leuven, BELGIUM, Boston, MA, US – March 20, 2023 – 11:30 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in... |
| 20.03.2023 | Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL | - |
| 02.03.2023 | Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding | - |
| 24.02.2023 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | /EIN News/ -- Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group Investment Ltd. has converted 80 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This ... |
| 12.12.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | /EIN News/ -- Negma Group has converted 380 convertible bonds in Oxurion resulting in a EUR 950,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel... |
| 12.12.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie | /EIN News/ -- Negma Group heeft 380 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 950.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen kapitaaltoezegging1 die aan Oxurion zal... |
| 02.12.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | /EIN News/ -- Negma Group has converted 322 convertible bonds in Oxurion resulting in a EUR 805,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel... |
| 02.12.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie | /EIN News/ -- Negma Group heeft 322 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 805.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen kapitaaltoezegging1 die aan Oxurion zal... |
| 18.11.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie | /EIN News/ -- Negma Group heeft 56 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 140.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen kapitaaltoezegging1 die aan Oxurion zal ... |
| 18.11.2022 | Oxurion kondigt tussentijdse analyse aan voor KALAHARI onderzoek | /EIN News/ -- Tussentijdse analyse voor KALAHARI onderzoek gepland tegen jaareinde 2022 met volledige top-line data verwacht in tweede helft van 2023
Leuven, BELGIË, Boston, MA, VS – 18 november 2022 – 22.00u CET Oxurion NV (Euronext Brusse... |
| 18.11.2022 | Oxurion Announces Interim Analysis for KALAHARI Trial | /EIN News/ -- Interim Analysis for KALAHARI trial planned by Year-End 2022 with Full Top-Line Data Expected in Second half of 2023
Leuven, BELGIUM, Boston, MA, US – November 18, 2022 – 10:00 PM CET Oxurion NV (Euronext Brussels: OXUR) a bio... |
| 18.11.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | /EIN News/ -- Negma Group has converted 56 convertible bonds in Oxurion resulting in a EUR 140,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel ... |
| 11.11.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | /EIN News/ -- Negma Group has converted 130 convertible bonds in Oxurion resulting in a EUR 325,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel... |
| 11.11.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie | /EIN News/ -- Negma Group heeft 130 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 325.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen kapitaaltoezegging1 die aan Oxurion zal... |
| 04.11.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Negma Group has converted 120 convertible bonds in Oxurion resulting in a EUR 300,000 capital increase. This is part of Negma Group's EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and different... |
| 04.11.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie | /EIN News/ -- Negma Group heeft 120 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 300.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen kapitaaltoezegging1 die aan Oxurion zal... |
| 28.10.2022 | Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie | /EIN News/ -- Negma Group heeft 580 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 1.450.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen kapitaaltoezegging1 die aan Oxurion z... |
| 28.10.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | /EIN News/ -- Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1,450,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its nov... |
| 28.10.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1,450,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differe... |
| 30.09.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Negma Group has converted 160 convertible bonds in Oxurion resulting in a EUR 400,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and different... |
| 03.09.2022 | Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding | Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular re... |
| 26.08.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and different... |
| 29.07.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Negma Group has converted 220 convertible bonds in Oxurion resulting in a EUR 550,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and different... |
| 11.07.2022 | Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences | Leuven, BELGIUM, Boston, MA, US – July 11, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, a... |
| 30.06.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds | Negma Group has converted 180 convertible bonds resulting in a EUR 450,000 capital increase and Kreos/Pontifax convertible bonds have been reimbursed in an amount of EUR 3 million
Leuven, BELGIUM, Boston, MA, US – June 30 , 2022 – 8.00 PM C... |
| 01.06.2022 | Oxurion to Participate in Upcoming Investor Conferences | Leuven, BELGIUM, Boston, MA, US – June 1, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, an... |
| 31.05.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and different... |
| 25.05.2022 | Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 | Leuven, Belgium, Boston, MA, US – May 25, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical s... |
| 09.05.2022 | Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) | Trial did not demonstrate efficacy on the key clinical endpoints
Oxurion to focus on its Phase 2 development program for THR-149
Leuven, BELGIUM, Boston, MA, US – MAY 9, 2022 – 8:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharma... |
| 06.05.2022 | Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022 | Leuven, Belgium, Boston, MA, US – May 6, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical st... |
| 05.05.2022 | Oxurion to Participate in Upcoming Conferences | Leuven, BELGIUM, Boston, MA, US – MAY 5, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders... |
| 03.05.2022 | Oxurion Announces Preclinical Data on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Leuven, BELGIUM, Boston, MA, US – May 3, 2022 – 7:10 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular re... |
| 29.04.2022 | Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA | Negma Group has converted 230 convertible bonds in Oxurion resulting in a EUR 575,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and different... |
| 11.04.2022 | Oxurion Announces Upcoming Pre-Clinical Data Presentation on THR-687 for the Treatment of Diabetic Macular Edema at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Leuven, BELGIUM, Boston, MA, US – 11 April 2022 – 7.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular ... |
| 01.04.2022 | Oxurion Announces Extraordinary and Annual Shareholders’ Meetings | Leuven, Belgium, Boston, MA, US - April 1, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical ... |
| 30.03.2022 | Information on the Total Number of Voting Rights (Denominator) following EUR > 10 million Private Placement and conversion notice from NEGMA | Oxurion has successfully raised EUR >10 million from leading US and European healthcare investors in a private equity placement and Negma Group has converted 240 convertible bonds in Oxurion resulting in a EUR 600,000 capital increase (a... |
| 28.03.2022 | Oxurion to Participate in Needham Virtual Healthcare Conference | Leuven, BELGIUM, Boston, MA, US - MARCH 28, 2022 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next generation standard of care ophthalmic thera... |
| 25.03.2022 | Oxurion Publishes 2021 Annual Report | Leuven, BELGIUM, Boston, MA, US - March 25, 2022 – 09.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical... |
| 17.03.2022 | Oxurion Receives Transparency Notifications from Fidelity Management & Research Company LLC and Novartis Pharma AG | Leuven, Belgium, Boston, MA, US - March 17, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical... |
| 07.03.2022 | Oxurion Successfully Closes EUR >10 Million in Private Placement | Led by new top-tier healthcare institutional investors along with participation by current major shareholders
Leuven, BELGIUM, Boston, MA, US - MARCH 7, 2022 – 10.00 AM CET – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or ... |
| 03.03.2022 | OXURION SUCCESSFULLY RAISES EUR >10 MILLION FROM LEADING US AND EUROPEAN HEALTHCARE INVESTORS IN A PRIVATE EQUITY PLACEMENT | Leuven, BELGIUM, Boston, MA, US - MARCH 3, 2022 – 08:00 AM CET – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next generation standard of care ophthalmic thera... |
| 14.02.2022 | Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference | Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four months of the trial after the last THR-149 injection with no rescue treatment required
These gains were seen in patients that are part of th... |
| 14.02.2022 | Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference | Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four months of the trial after the last THR-149 injection with no rescue treatment required
These gains were seen in patients that are part of th... |
| 11.02.2022 | Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference | Leuven, BELGIUM, Boston, MA, US – 11 February 2022 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascul... |
| 11.02.2022 | Oxurion Announces Upcoming Presentation on THR-149 Phase 2 Clinical Trial (“KALAHARI”) at the Angiogenesis, Exudation, and Degeneration 2022 Conference | Leuven, BELGIUM, Boston, MA, US – 11 February 2022 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascul... |
| 08.02.2022 | Oxurion to Participate in the 2022 BIO CEO and Investor Conference | Leuven, BELGIUM, Boston, MA, US – February 8, 2022 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascu... |
| 18.01.2022 | OXURION to Participate in the 10th edition of Degroof Petercam’s Healthcare Conference | Leuven, BELGIUM, Boston, MA, US – January 18, 2022 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascu... |
| 07.01.2022 | Oxurion Provides Update on Clinical Pipeline Progress | Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve subjects
US IRB Approval of Protocol Amendment to Part B of the Phase 2 KALAHARI Trial Ass... |
| 04.01.2022 | OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference | Leuven, BELGIUM, Boston, MA, US – January 4, 2022 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascul... |
| 04.01.2022 | OXURION to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference | Leuven, BELGIUM, Boston, MA, US – January 4, 2022 – 06.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascul... |
| 30.11.2021 | Information on the Total Number of Voting Rights (Denominator) following conversion notices from NEGMA | Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and different... |
| 24.11.2021 | OXURION to Present at the Ophthalmology Day at BTIG | Leuven, BELGIUM, Boston, MA, US - November 24, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vasc... |
| 22.11.2021 | OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures | Provides Additional Capital to further Develop the Company’s Innovative Pipeline of Novel Clinical Assets, THR-687 and THR-149
Leuven, BE, Boston, MA, US – November 22, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharma... |
| 22.11.2021 | OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures | Provides Additional Capital to further Develop the Company’s Innovative Pipeline of Novel Clinical Assets, THR-687 and THR-149
Leuven, BE, Boston, MA, US – November 22, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharma... |
| 15.11.2021 | OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME) | THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 50% of the patient population suboptimally responding to anti-VEGF therapy
Leuven, BE, Boston, MA, US – 15 November 2021 – 07.00 AM CET – Oxurion NV (Eu... |
| 15.11.2021 | OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME) | THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 50% of the patient population suboptimally responding to anti-VEGF therapy
Leuven, BE, Boston, MA, US – 15 November 2021 – 07.00 AM CET – Oxurion NV (Eu... |
| 04.11.2021 | Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation | Leuven, BE, Boston, MA, US – November 4, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular r... |
| 13.10.2021 | Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME) | THR-687 is a potent pan-RGD integrin antagonist holding potential as a next generation first line therapy for DME, currently a $4.5 billion market opportunity
THR-687 also holds promise for treatment of wet AMD (Age-related Macular Degenera... |
| 11.10.2021 | OXURION - Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Specialists (ASRS) Annual Scientific Meeting | Patients in the highest dose group achieved an overall mean 6.1 letter improvement in Best Corrected Vision (BCVA) at Month 3, of which:
63% showed at least a 5-letter gain
38% achieved at least a 10-letter gain
13% achieved at least a 15-l... |
| 05.10.2021 | OXURION to Present at the Lytham Partners Fall 2021 Investor Conference | Leuven, BELGIUM, Boston, MA, US – 5 October, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascul... |
| 30.09.2021 | Oxurion : Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) | Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data
Oxurion is moving into Part B of study evaluating THR-149 against aflibercept
THR-149 is a pot... |
| 17.08.2021 | Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal | THR-687 is a potent pan-RGD integrin antagonist holding potential as next generation first line therapy for DME, wet AMD and RVO
Phase 2 Clinical Study THR-687 in DME currently recruiting patients
Leuven, BE, Boston, MA, US – August 17, 202... |
| 05.08.2021 | OXURION : to Participate in Upcoming Investor Meetings | Leuven, BELGIUM, Boston, MA, US - August 5th, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascu... |
| 10.06.2021 | OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME) | THR-687 is a potent pan-RGD integrin antagonist
holding potential as next generation first line therapy for DME
Leuven, BE, Boston, MA, US – June 10, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company de... |
| 17.05.2021 | OXURION NV Appoints Tom Graney, CFA as Chief Executive Officer | Patrik De Haes M.D. becomes Non-executive Chairman
Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapi... |
| 13.04.2021 | OXURION NV to Present at Wet AMD and DME Drug Development Summit | Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical stage portfolio in retinal vas... |
| 07.04.2021 | Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD | Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year
Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Eurone... |
| 07.04.2021 | OXURION NV
Oxurion : Publication in 'Progress in Retinal and Eye Research' highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD | Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, announces the publication of a review article describing the cutting-edge science and ra... |
